Abstract
The effect of intraocular injections of anti-vascular endothelial growth factor (VEGF) on intraocular pressure (IOP) has not been clearly stated. We extracted data from the electronic health records at Dijon University Hospital of 750 patients who were unilaterally injected with anti-VEGF agents between March 2012 and March 2020. These were treatment-naïve patients who had received at least three injections of the same treatment (aflibercept, bevacizumab, or ranibizumab) in one eye only, and had IOP measurements before and after the injections. Fellow untreated eyes were used as comparators. A clinically significant IOP rise was determined as an IOP above 21 mmHg and an increase of at least 6 mmHg compared to baseline, or the need for IOP-lowering agents. We found an overall slight increase in IOP between treated and untreated eyes at 6 months (+0.67 ± 3.33 mmHg, 95% confidence interval 0.33–1.02, p < 0.001). Ranibizumab had a higher final IOP at 1 and 3 months. Age, sex, and the number of injections were not associated with IOP variation. Ranibizumab was associated with a higher rate of increase in clinically significant IOP at 6 months (p = 0.03). Our study confirms that anti-VEGF injections constitute a relatively safe treatment regarding their impact on IOP.
Highlights
Various retinal diseases can lead to central vision impairment
In high-income countries, population aging has led to an increase in chronic diseases, such as choroidal neovascularization in age-related macular degeneration (AMD), which is one of the main causes of irreversible blindness [1]
Other retinal conditions, such as high myopia, retinal vein occlusion (RVO), and diabetic macular edema (DME), may lead to severe central vision impairment if left untreated, and these conditions have seen a significant increase in prevalence [2]
Summary
In high-income countries, population aging has led to an increase in chronic diseases, such as choroidal neovascularization in age-related macular degeneration (AMD), which is one of the main causes of irreversible blindness [1] Other retinal conditions, such as high myopia, retinal vein occlusion (RVO), and diabetic macular edema (DME), may lead to severe central vision impairment if left untreated, and these conditions have seen a significant increase in prevalence [2]. These diseases have a major impact on the quality of life of patients and represent a heavy burden on public health costs [3,4]. Important to study the occurrence of adverse events after IVTs, such as increased intraocular pressure (IOP) [7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
